Breaking Protocol

Tilda
  • 0,0 (0)
  • БИОНАУКИ

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.

Выпуски

  1. -6 ДН.

    Alex Mok: Building Biotechs in the AI Era

    Drug development is both a science challenge and timeline challenge. In this episode, Alex Mok shares what it actually takes to build a biotech company in today’s market. From launching an specialized therapeutics platforms to navigating shifting capital markets, Alex breaks down how valuation, risk, and execution intersect in modern drug development.We explore why clinical trial timelines directly shape risk-adjusted NPV, how market cycles influence platform vs. asset strategies, and why operational execution has become the real competitive advantage in biotech.Alex also shares a deeply personal story about trying to enroll his own father in a Phase 1 oncology trial — a firsthand look at how broken clinical operations can delay care and destroy value.The conversation covers timely topics such as AI-native clinical operations, agentic workflows in biotech, capital efficiency in drug development, the impact of automation on enrollment and trial velocity, and what happens when execution risk is materially reduced. If AI meaningfully lowers the cost and friction of clinical development, the biotech landscape changes. More shots on goal, faster proof of concept and different capital dynamics. This episode is for biotech founders, pharma executives, clinical operations leaders, and investors thinking about where the industry goes next.

    1 ч.

  2. 3 МАР.

    Paula Brown Stafford: Modernizing Trials Without Breaking Them

    In this episode of Breaking Protocol, Ram Yalamanchili sits down with Paula Brown-Stafford, CEO of Allucent and one of the early architects of the CRO industry. From joining Quintiles as its 23rd employee to leading a purpose-built CRO focused on biotech innovation, Paula shares how the industry evolved from pure operational execution to intelligence-driven partnership. She explains why the real differentiator today is not scale, but regulatory intelligence, therapeutic depth, and the ability to navigate complex rare disease and cell and gene therapy trials. The conversation also examines the economics of drug development, shifting regulatory pathways, and how AI teammates can reduce time and cost without compromising quality. For sponsors facing capital constraints and increasing pressure to deliver results, this episode offers a grounded perspective on how the CRO model must evolve to create measurable strategic advantage. If you are leading clinical development, R&D, or portfolio strategy, this discussion will challenge how you think about partnership, value, and execution.

    50 мин.

  3. 18 ФЕВР.

    Dr. Tom Mather: De-risking Drug Development with AI

    In this episode of Breaking Protocol, Tilda Research CEO Ram Yalamanchili sits down with Dr. Tom Mather — Chief Medical Officer of a clinical-stage biotech, early-stage venture investor, and marathoner — to unpack the real bottlenecks in drug development.From seed-stage funding to Phase III trials, Tom shares a rare perspective of clinician + operator + investor.They discuss:• Why venture capital hasn’t disappeared but is demanding de-risking• The growing gap between discovery and clinical execution• Why clinical trials remain the largest financial and operational bottleneck• How machine learning can improve early data, trial design, and protocol development• What happens when AI enables more molecules than the system can handle• Why Tom rejects the term “artificial” intelligenceIf AI accelerates discovery, but clinical infrastructure stays manual and siloed, the bottleneck only shifts downstream.This conversation explores what that future could look like.

    46 мин.

  4. 23.07.2025

    Dr. Mark Barakat: How AI reinvents clinical trials

    What happens when a retina specialist with a background in computer science takes on the inefficiencies of clinical research?In this insightful conversation, Dr. Mark Barakat of Retina Macula Institute joins Tilda CEO Ram Yalamanchili to explore how AI is transforming the day-to-day reality of clinical trial execution.They discuss the growing operational burdens on site staff, the silent cost of turnover, and the bottlenecks that limit research capacity. Dr. Barakat shares his firsthand experience adopting AI in a high-volume ophthalmology research site—including what’s working, what’s not, and why he believes AI will become a core collaborator, not a threat.From automating data entry and managing re-consent workflows to long-term visions of AI-assisted imaging and protocol compliance, this episode offers a grounded, site-level perspective on AI’s real potential in trial operations.⸻What you’ll learn:- How AI is reducing operational burden for clinical research coordinators and site staff- Why research sites struggle with staff burnout, turnover, and training and how AI can help- The hidden inefficiencies in clinical trial workflows (EDC, source-to-CRF, informed consent)- Real-world examples of AI improving regulatory compliance and data quality at ophthalmology sites- How sites are using AI to manage high trial volume without increasing headcount- Why adoption of AI in clinical research is slow—and what’s changing now- The role of AI in imaging analysis for retina trials, including OCT segmentation and atrophy tracking- How AI can level the playing field across high- and low-performing clinical trial sites- Practical considerations for bringing AI into day-to-day research operations- What sponsors need to know about site enablement, trial scalability, and AI’s role in quality assurance

    26 мин.

  5. 30.06.2025

    Dr. Houman Hemmati: Clinical Trials Fail in the Execution: It doesn't have to be this way

    In a recent conversation, Dr. Houman Hemmati (ophthalmologist, clinical trialist, and biotech innovator) didn’t hold back in describing the systemic inefficiencies he sees every day. From sponsor overreach to CRO micromanagement to administrative overload at research sites, the entire model is built to sustain activity, not outcomes. He believes that AI can eliminate a lot of the operational drag that wastes time and wears people down. And he predicted a lot of the AI-centric changes that have been announced by the FDA recently.

    46 мин.

  6. 02.06.2025

    Dr. James Fox: Scaling Clinical Research with AI Teammates

    ICON Eyecare experiences 66% data quality improvement and 90% increase in efficiency. Dr. James Fox of ICON Eyecare (Grand Junction, CO) discusses what it really takes to scale clinical research today. He walks through the burnout his team faced, the turning point that led to adopting AI teammates, and the measurable improvements in data quality, team capacity, and growth. He unpacks the staffing paradox in research, the trust that's at stake, and what it means for the future when AI and humans work side-by-side. His site, running 30 trials with a lean team, is a case study in what happens when AI meets the real-world pressure of clinical operations.

    56 мин.

  7. 27.05.2025

    Dr. David Chin Yee: Streamlining Clinical Trials

    Transforming Clinical Trials with AI: An in-depth Discussion with Dr. David Chin YeeDr. David Chin Yee, Research Director at Georgia Retina shares his journey and the transformation of the practice with the use of AI teammates. Georgia Retina is one of the largest private practice retina groups in the Southeast. As an early adopter of AI to streamline clinical research, he discusses the integration of AI into his studies, how he's dealing with challenges of high staff turnover, and the critical role of efficient systems in improving clinical research outcomes. Learn about the future of AI in ophthalmology and the steps Dr. Chin Yee is taking to make Georgia Retina a top-tier clinical trial site.

    35 мин.

  8. 18.05.2025

    Dr. George Magrath: How Opus Breaks Trial Bottlenecks

    A powerful conversation with Dr. George Magrath, CEO of Opus Genetics and seasoned ophthalmologist, as he shares how AI is reshaping clinical trials, and the incredible impact of AI teammates on his clinical research program. From cutting trial timelines to boosting enrollment, George reveals real-world wins in biotech and gene therapy for rare childhood blindness. Opus' near sci-fi levels of science is restoring vision for blind adults. Learn how AI is easing site coordinator burden, accelerating research, and making once-impossible treatments a reality.

    48 мин.
  • Выпусков: 8

Об этом подкасте

The clinical trial industry is stuck in an innovation impasse, weighed down by outdated processes, layers of bureaucracy, and a systemic inability to prioritize those on the frontlines - patients, sites, and researchers. Tune in every week as Tilda Research CEO Ram Yalamanchili interviews clinical trial leaders at the cutting edge of innovation who are breaking past the current paradigm.

Информация

  • Автор
    Tilda
  • Годы выхода
    2025 - 2026
  • Выпуски
    8
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © Tilda
  • Сайт подкаста
    Breaking Protocol